This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit |   AhHa B2B Search:     

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Sep. 27, 2012


Benchmarking in the process of donation after brain death: A methodology to identify best performer hospitals
American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A benchmarking approach was developed in Spain to identify and spread critical success factors in the process of donation after brain death. This paper describes the methodology to identify the best performer hospitals in the period 2003–2007 with 106 hospitals throughout the country participating in the project. More


Have REMS questions? AST has answers... in less than 15 minutes
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Visit AST's newly created Risk Evaluation and Mitigation Strategies (REMS) Resource Center to listen to a brand new podcast; a conversation between Dr. Richard Formica (Yale University) and Steven Gabardi, PharmD (Harvard Medical School). Drs. Formica and Gabardi address questions important to all transplant professionals dealing with REMS, and provide a follow up to the December 2010 REMS podcast. The resource center will be updated in the coming weeks and months to provide you with the tools you need to address issues involving REMS.

ESOT-AST Joint Meeting: Transformational Therapies and Diagnostics in Transplantation
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The ESOT-AST Joint Meeting is less than a month away, but there is still time to register at discounted rates. Register by Friday, Sept. 21 to save; register and view the program on the ESOT website, in the "Meetings" section. Faculty and attendees will critically analyze important topics such as the results of recent clinical trials using costimulation blockade, new challenges in the diagnosis and treatment of antibody mediated rejection, pharmacogenetic testing in patient management, new immunosuppressive agents in the pipeline, new interventions for delayed graft function and graft fibrosis and current immunosuppressive therapies and identify unfulfilled needs and potential new interventions. Transformational Therapies and Diagnostics in Transplantation will be held on Oct. 12-14 at Palais de la Méditerranée in Nice, France.

AST awards program: Nominate your colleagues
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
AST is soliciting nominations for AST Achievement Awards. The deadline for submissions is Nov. 19. AST sponsors a variety of achievement awards according to faculty rank in recognition of the AST members' achievements and contributions to the field of transplantation. AST members are encouraged to nominate deserving candidates for consideration. For complete information on awards eligibility criteria, application requirements, the review process and to submit a nomination, please visit the awards section of the AST website.

AST grants program: Submit an application for funding
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The American Society of Transplantation (AST) is now accepting applications for AST faculty and fellowship grants. The deadline for submissions is Nov. 19, 2012. AST grants support a wide range of basic and clinical research topics. AST members should bring this program to the attention of their colleagues in the field of transplantation at their institutions and support their applications. For complete information on grants eligibility criteria, application requirements, funding guidelines, the review process and to submit an application, please visit the grants section of the AST website.

Submit abstracts now for AST's Cutting Edge of Transplantation (CEOT) 2013 meeting
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
"B Cells from Bedside to Bench to Bedside: A Comprehensive Look at B Cells and Antibodies in Transplantation," will be held Feb. 14-16, 2013 in Phoenix, at the Sheraton Wild Horse Pass. The Cutting Edge of Transplantation (CEOT) meeting is a multi-expert view of the most important clinical and research problems in B cells and antibodies in transplantation. Abstract submission is now open and you can view the program online. Clinical, basic and translational abstracts related to the meeting topic will be considered. Submit as many as you'd like before the Oct. 31 deadline.

Come together to discuss the state-of-the-art in the vital area of B cells and antibodies in transplantation, including clinical management decisions from diagnosis to desensitization to therapy and the basic research questions that inform this field and create new directions for the future. Sessions include:
  • Clinical Problems with Antibodies in Transplantation
  • Biology of B Cells and Plasma Cells
  • What is Antibody-Mediated Rejection (AMR)?
  • Avoiding and Treating the Problem
  • Features of AMR
  • B Cells and Antibody-mediated Allograft Injury
  • Controversies: Antibodies in Transplantation


    C1qScreen™: A New Research Tool for AMR Risk
    Identify Antibodies That May Compromise Graft Survival
    • Detect Presence of Complement Fixing Antibodies
    • Investigate risk of developing Antibody Mediated Rejection (AMR)
    Request a Complimentary Sample Kit!

    For Research Use Only. Not for use in diagnostic procedures.

    Gastroesophageal reflux disease-induced aspiration injury following lung transplantation
    Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Recent findings support ubiquitous testing for gastroesophageal reflux disease or aspiration in patients with end-stage lung disease both pretransplant and posttransplant and demonstrate that fundoplication can safely and effectively protect these patients from the ongoing injury of GERD-induced pulmonary injury. More

    Kidney transplant waiting list faces revisions
    The Legal Examiner    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    The United Network for Organ Sharing has proposed a new scheme for distributing deceased-donor kidneys among the 93,000 people currently waiting for a transplant. UNOS handles organ procurement and transplantation pursuant to a contract with the federal Department of Health and Human Services.

    Related articles:
    Kidney transplant policy may change (KDLT-TV)
    Discarded kidneys (The New York Times)

    Immediate renal transplantation after radical prostatectomy for low-risk prostate cancer
    Clinical Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    For most cancers, a two- to five-year period with no evidence of disease must be demonstrated before organ transplantation. The natural history of prostate cancer is unique both because of extensive pre-treatment screening and the ease of post-treatment monitoring for recurrence. Using available predictive models for prostate cancer recurrence, researchers examined whether current evidence supports a prolonged waiting period after radical prostatectomy and before renal transplantation. More

    Reduction of lipid-laden macrophage index after laparoscopic Nissen fundoplication in cystic fibrosis patients after lung transplantation
    Clinical Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Lipid-laden macrophage (LLM) index could be potentially useful in assessing gastroesophageal (GE) reflux and aspiration after lung transplantation (LT) in patients with cystic fibrosis (CF). A retrospective review of CF patients undergoing LT and/or laparoscopic Nissen fundoplication (LNF) from Jan. 1, 2009, to Dec. 31, 2011, was performed. Significant reduction in the LLM index occurred after LNF in CF patients after LT that correlated with resolution of clinical symptoms of GE reflux. More

    Athena Diagnostics

    Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.

    'Snipping' transplant complications
    Ivanhoe Broadcast Newswire    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Bone marrow transplant patients face the risk of complications even after the actual procedure is finished. Graft-versus-host disease affects 80 percent of patients, posing a serious issue for the patients themselves and a complicated problem many doctors and researchers have tried to understand and solve. Now a new discovery may open the doors to finding better donor matches and hopefully cutting the number of transplant patients who develop GVHD. More

    Ex-vivo lung perfusion
    Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Lung transplant continues to be hampered by the number of available donors. Ex-vivo lung perfusion (EVLP) has emerged as an essential tool for the reassessment, under a controlled scenario, of lungs that initially did not meet transplantation criteria. EVLP has already proved its value as a tool to identify 'good' lungs from the previously rejected pool. But as new therapeutics arise, EVLP will also prove its value as a reproducible platform for their evaluation. More

    Costimulation blockade – A double-edged sword?
    American Journal of Transplantation    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Costimulation blockade with CTLA-4Ig is an exciting and recently FDA approved immunomodulatory strategy in treatment of autoimmune disease and kidney transplantation. Initially described more than 20 years ago, abatacept and the modified form, belatacept are fusions of the extracellular portion of CTLA-4 with an immunoglobulin Fc region. The overall clinical effect of CTLA-4Ig administration is to dampen effector T-cell mediated responses. A recent report in American Journal of Transplantation and another in this issue add to a growing body of literature complicating this view by showing that CTLA-4Ig can accelerate rejection thus reminding us that costimulation blockade can have opposing functional effects on T-effector versus T-regulatory cells. More

    AST eNews

    Colby Horton, Vice President of Publishing, 469.420.2601
    Download media kit

    Courtney Hodges, Content Editor, 972.402.2604   
    Contribute news

    This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

    Recent issues
    Sept. 20, 2012
    Sept. 13, 2012
    Sept. 6, 2012
    Aug. 31, 2012

    7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063